Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
Infinimmune raised $75M to take two human-derived antibodies into atopic dermatitis. One hits IL-13, the validated target. The other targets IL-22, which no approved biologic has ever drugged. Regeneron, which owns the market leader, co-led the round.
A second positive Phase 3 readout for Definium's LSD-based DT120 resets anxiety-market expectations. The September Panorama study is the next binary.
Ratio Therapeutics raised $70 million to push actinium-225 targeted alpha therapy through its ATLAS Phase 1/2 sarcoma trial and expand manufacturing. The real bet is on the isotope: supply, not trial design, has been the field's bottleneck.
Mint Innovation spun its battery-recovery business into a separate company, Linca, backed by an £8.1 million UK consortium including Jaguar Land Rover and the University of Warwick. The solvent-free process targets the 85% of global black mass refining that happens in China.
One drug in ten survives Phase 1. The rest of the base-rate curve — and how the market prices it — in five minutes.
LifeMine closed $263M across Series D and E, led by Milky Way with Bezos and Gates as new backers, for LIFE-001: a fungal-genome calcineurin inhibitor that keeps immunosuppression but drops tacrolimus kidney damage. Reads: kidney Phase 2 and islet Phase 1b, data 2027-2028.
Contraline raised a $92.5M Series B to fund NES/T, a once-daily hormonal gel, through Phase 3 and advance ADAM, a non-hormonal implant, toward the first reversible male contraceptive product. It weighs a funded pipeline against the acceptance gap that sank earlier programs.
A balanced GLP-1/glucagon agonist reduced heavy drinking days in alcohol use disorder. The readout is real, the trial is small, and the market that is still open makes the next phase the one that counts.
Get daily updates on the technologies and investment opportunities shaping the next decade — from AI infrastructure and autonomous systems to biotech, space, and defence. Curated analysis, no noise.
